Advertisement
Canada markets close in 6 hours 30 minutes

  • S&P/TSX

    21,805.05
    -68.67 (-0.31%)
     

  • S&P 500

    5,019.88
    -51.75 (-1.01%)
     

  • DOW

    38,052.09
    -408.83 (-1.05%)
     

  • CAD/USD

    0.7287
    -0.0011 (-0.15%)
     

  • CRUDE OIL

    82.57
    -0.24 (-0.29%)
     

  • Bitcoin CAD

    86,725.09
    -3,937.02 (-4.34%)
     

  • CMC Crypto 200

    1,346.44
    -36.13 (-2.62%)
     

  • GOLD FUTURES

    2,325.80
    -12.60 (-0.54%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.7250
    +0.0730 (+1.57%)
     

  • NASDAQ

    15,712.75
    +16.11 (+0.10%)
     

  • VOLATILITY

    17.00
    +1.03 (+6.45%)
     

  • FTSE

    8,050.75
    +10.37 (+0.13%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6816
    -0.0003 (-0.04%)
     
MARKETS LIVE BLOG:

STOCK FUTURES SLIDE AFTER META'S REALITY CHECK, WITH GDP ON DECK

Owner of Facebook and Instagram plans to spend up to US$10B on AI infrastructure investments

Bayer says its drug extends lives of liver cancer patients

Reuters
The corporate logo of Bayer is seen at the headquarters building in Caracas May 6, 2015. REUTERS/Carlos Garcia Rawlins (Reuters)

FRANKFURT (Reuters) - Bayer AG said on Thursday its Regorafenib cancer treatment drug helped extend the lives of liver cancer sufferers according to the results of a Phase III clinical trial. Bayer now plans to file for regulatory approval of the oncology compound, which is also know as Stivarga, it said. The German company said it plans to submit the data from its study as the basis for marketing authorisation of Regorafenib in the treatment of inoperable liver cancer in 2016. (Reporting by Edward Taylor; Editing by Alexander Smith)